eligibility_summary
Adults ≥18 (≤75 if climbing) with relapsed/refractory CLL/SLL after BTKi or NHL after ≥2 prior lines incl anti‑CD20, measurable disease, ECOG ≤2, life ≥3 mo, AEs ≤G1, adequate marrow/renal/hepatic/coag, contraception, compliant. Exclude: recent major surgery, ILD/grade ≥3 lung disease, severe infection, active autoimmune, other cancers <3y, HIV/TB/HBV/HCV, uncontrolled HTN, LVEF ≤45%/major cardiac/QT, allergy, pregnancy, CNS disease, organ/allo‑HSCT, recent auto‑HSCT/CAR‑T/anti‑CD20/RT/chemo/targeted/immunosuppressants/other trials, unsuitable.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial: NCT05944978 (Phase Ib/II, single-arm). Intervention: GNC-035, an investigational tetra-specific (quad-specific) antibody biologic, given by weekly IV infusion. Mechanism/type: Multispecific immunotherapy antibody designed to bind multiple targets simultaneously to enhance anti-tumor immune activity, specific antigen targets are not listed in the registry. Intended action is immune-mediated killing of malignant cells and mitigation of antigen-escape through multi-antigen recognition. Cells/pathways targeted: Malignant B cells in relapsed/refractory CLL/SLL and other non-Hodgkin lymphomas. Pathways involve immune effector engagement against hematologic B-cell malignancies (precise targets/signaling pathways not specified).